Axxcess Wealth Management LLC Has $214,000 Stock Holdings in Sanofi (NASDAQ:SNY)

Axxcess Wealth Management LLC decreased its position in Sanofi (NASDAQ:SNY) by 45.5% during the 4th quarter, Holdings Channel.com reports. The fund owned 4,440 shares of the company’s stock after selling 3,713 shares during the quarter. Axxcess Wealth Management LLC’s holdings in Sanofi were worth $214,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. boosted its holdings in Sanofi by 31.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company’s stock valued at $8,040,000 after acquiring an additional 33,105 shares during the last quarter. Arkadios Wealth Advisors boosted its holdings in Sanofi by 19.0% in the fourth quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company’s stock valued at $227,000 after acquiring an additional 751 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Sanofi by 7.1% during the third quarter. Geode Capital Management LLC now owns 254,738 shares of the company’s stock worth $14,681,000 after buying an additional 16,780 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Sanofi by 20.9% during the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock worth $133,172,000 after buying an additional 399,301 shares during the last quarter. Finally, Kentucky Trust Co bought a new position in Sanofi during the fourth quarter worth about $436,000. Institutional investors own 14.04% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on SNY shares. The Goldman Sachs Group started coverage on Sanofi in a report on Friday. They set a “neutral” rating and a $65.00 target price on the stock. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Three equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $62.50.

Sanofi Trading Down 1.5 %

NASDAQ:SNY opened at $56.90 on Friday. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $60.12. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The stock has a market capitalization of $144.40 billion, a PE ratio of 22.85, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. The business’s 50-day simple moving average is $54.55 and its 200-day simple moving average is $52.89.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Sell-side analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.